Overview

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-24

Target enrollment:

Participant gender:

Summary

People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

suvorexant